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Abstract
Background: It is well established that sexual differentiation of the rodent hypothalamic-pituitary-gonadal (HPG)
axis is principally orchestrated by estrogen during the perinatal period. Here we sought to better characterize the
mechanistic role the beta form of the estrogen receptor (ERb) plays in this process.
Methods: To achieve this, we exposed neonatal female rats to three doses (0.5, 1 and 2 mg/kg) of the ERb
selective agonist diarylpropionitrile (DPN) using estradiol benzoate (EB) as a positive control. Measures included day
of vaginal opening, estrous cycle quality, GnRH and Fos co-localization following ovariectomy and hormone
priming, circulating luteinizing hormone (LH) levels and quantification of hypothalamic kisspeptin immunoreactivity.
A second set of females was then neonatally exposed to DPN, the ERa agonist propyl-pyrazole-triol (PPT), DPN
+PPT, or EB to compare the impact of ERa and ERb selective agonism on kisspeptin gene expression in pre- and
post-pubescent females.
Results: All three DPN doses significantly advanced the day of vaginal opening and induced premature anestrus.
GnRH and Fos co-labeling, a marker of GnRH activation, following ovariectomy and hormone priming was reduced
by approximately half at all doses; the magnitude of which was not as large as with EB or what we have
previously observed with the ERa agonist PPT. LH levels were also correspondingly lower, compared to control
females. No impact of DPN was observed on the density of kisspeptin immunoreactive (-ir) fibers or cell bodies in
the arcuate (ARC) nucleus, and kisspeptin-ir was only significantly reduced by the middle (1 mg/kg) DPN dose in
the preoptic region. The second experiment revealed that EB, PPT and the combination of DPN+PPT significantly
abrogated preoptic Kiss1 expression at both ages but ARC expression was only reduced by EB.
Conclusion: Our results indicate that selective agonism of ERb is not sufficient to completely achieve male-typical
HPG organization observed with EB or an ERa agonist.
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Background
The relative mechanistic roles the two primary forms of
the estrogen receptor (ERa and ERb) play in the estrogen-
dependent organization of the hypothalamic-pituitary-
gonadal (HPG) axis remain incompletely characterized.
The present study addressed this data gap by assessing the
impact of ER-selective agonism during neonatal life on
HPG organization. Within the HPG axis, reproductive
maturation and function is largely coordinated by the
release of gonadotropin releasing hormone (GnRH) [1,2].
In the adult, GnRH secretion is regulated by positive and
negative steroid feedback loops. These hormone sensitive,
neuroendocrine pathways are sexually dimorphic and
organized, primarily, by hormones in a series of perinatal
critical periods. In adult females, a “surge” of GnRH, eli-
cited through positive feedback by the pre-ovulatory rise
of estradiol, induces the release of luteinizing hormone
(LH) and, consequently, ovulation. In male rodents, neo-
natal estrogen, aromatized from testicular androgen, acts
within the HPG axis to defeminize the male hypothalamus
such that GnRH neurons do not respond to elevated
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any medium, provided the original work is properly cited.estrogen levels with a surge of GnRH. Similarly, neonatal
estrogen administration can also defeminize the female
hypothalamus resulting in the inability to generate a
GnRH surge in adulthood [3].
We have previously shown that neonatal administra-
tion of estradiol benzoate (EB) or the ERa selective ago-
nist propyl-pyrazole-triol (PPT) to female rats results in
the premature onset of anestrus and, following ovariect-
omy (OVX) and hormone priming, little to no Fos label-
ing in GnRH neurons (an indicator of GnRH activation)
[4,5]. These effects signify the incapacitation of the ster-
oid positive feedback system. In contrast, while neonatal
administration of the ERb selective agonist diarylpropio-
nitrile (DPN) also impacted estrous cyclicity and GnRH
activation to some degree, the magnitude of each effect
was considerably smaller compared to EB or PPT
administration [4]. For example, most DPN exposed
females ultimately developed an irregular estrous cycle,
but this occurred several weeks after females exposed to
PPT or EB became anestrus, most of which were acyclic
within days of pubertal onset. GnRH and Fos co-labeling
was approximately 41% lower in the DPN exposed ani-
mals compared to control females, but this decline was
not statistically significant. Collectively, these results
c o u l di n d i c a t et h a te i t h e r( 1 )t h ed o s eo fD P Nu s e di n
our prior study was insufficient to produce a maximal
effect, or (2) that ERb plays a less critical mechanistic
role than ERa in the defeminization of GnRH signaling
pathways. The first experiment in the present study was
u n d e r t a k e nt od e f i n i t i v e l yr e s o l v et h i si s s u eb ym o r e
comprehensively examining the relative role ERb might
play in the sex specific organization and function of the
HPG axis.
Although GnRH neurons express ERb, and thus can
potentially respond to DPN directly, it is generally
accepted that hormonal signals are largely coordinated
by other estrogen responsive neurons within the
hypothalamus, which then convey this information to
the GnRH neurons [3,6]. One group of neurons that has
recently emerged as critical regulators of GnRH secre-
tion are those which produce kisspeptin (Kiss), a family
of proteins coded for by the Kiss1 gene. There is rapidly
emerging evidence that Kiss neurons directly innervate
GnRH neurons and are vital for the regulation of GnRH
secretion in many species, including humans [7-12]. The
kisspeptin receptor (Kiss1r, formerly GPR54) is constitu-
tively expressed in GnRH neurons [13-16]. Activation of
this receptor was demonstrated to be required for the
initiation of puberty with the discovery that humans or
mice with a mutated form of Kiss1r fail to enter puberty
and remain hypogonadal [17,18].
In the rat, there are two major populations of Kiss
neurons, a preoptic population spanning the anteroven-
tral periventricular nucleus (AVPV) through the medial
preoptic area (MPOA), and one in the arcuate nucleus
(ARC). The density of Kiss neurons appears to be sexu-
ally dimorphic only in the AVPV, with females having
significantly more Kiss neurons, Kiss1 expression and
Kiss immunoreactive (-ir) neuronal fibers than males
[19-22]. This population is thought to be essential for
steroid positive feedback and the initiation of the pre-
ovulatory GnRH surge [7,9,13,23-25]. The importance of
neonatal estrogen for male-typical organization of
AVPV Kiss neurons has been demonstrated by us and
others. Neonatal administration of aromatizable andro-
gen [26] reduces Kiss1 expression, while EB or the ERa
selective agonist PPT produces male-like levels of Kiss-ir
in the rat female AVPV [4,20]. This defeminizing influ-
ence of estrogen during the neonatal period is consistent
with what is currently known about the structural orga-
nization of the AVPV and the sex specific organization
of other neuronal populations contained within it
[3,27,28]. By contrast, a role for ERb in the sexual differ-
entiation process has not been clearly established. In the
first experiment, using multiple doses of the ERb agonist
DPN, we sought to more definitively determine whether
or not neonatal activation of ERb could also defeminize
Kiss-ir in the hormone primed, ovariectomized female
rat. A subsequent experiment was then performed to
compare how DPN, PPT or the co-administration of
both influences the peripubertal ontogeny of Kiss1
expression in gonadally intact females to obtain a com-
prehensive picture of how ER selective agonism impacts
the kisspeptin system across the lifespan.
The ARC population of Kiss neurons is hypothesized
to be important for the regulation of steroid negative
feedback and energy balance [22,26,29]. Potential sex
differences within this population remain incompletely
characterized. The density of ARC Kiss-ir fibers is
clearly greater in post-pubertal females than males [30].
We have shown that neonatal administration of EB sig-
nificantly reduces Kiss-ir in the female rat ARC suggest-
ing that estrogen plays an important role in organizing
this sex difference. Interestingly, although it was initially
shown that the number of Kiss-1 expressing neurons
and the density of Kiss1 expression in the ARC is not
sexually dimorphic in adults [26] recent work has sug-
gested that the influence of steroid hormone-indepen-
dent factors on the function of these neurons is sexually
dimorphic during peripuberty [31]. This sex difference
is most likely attributable to known sex differences in
the tempo of pubertal maturation in rodents, with males
maturing later than females. This observation indicates
that the ARC population may be functionally dimorphic
to some degree and thus influenced by neonatal estro-
gens. We recently revealed robust sex differences in
ARC Kiss1 expression prior to weaning (but not after),
supporting the hypothesis that neonatal estrogens have
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ARC Kiss system [4,20]. We have previously demon-
strated that neonatal administration of the ERa selective
agonist PPT results in only a marginal decrease in ARC
Kiss-ir fibers, suggesting that agonism of ERa alone is
insufficient to recapitulate the effect of EB [4,20]. Simi-
larly, neonatal administration of DPN at 1 mg/kg did
not appreciably affect the density of ARC Kiss-ir fibers
[4]. The plexus of the Kiss-ir fibers in the rat ARC is
dense, making neuron number difficult to ascertain.
Thus, the impact of estrogens on the number of Kiss
neurons has not been clearly established. Moreover, the
relative roles ERa and ERb play in the organization of
the ARC Kiss1 population remain undefined. The pre-
sent experiments fill this data gap by characterizing the
effects of DPN, PPT, or the co-administration of both,
on Kiss1 mRNA and Kiss-ir in the ARC.
DPN is an ERb selective agonist with a 70-fold greater
relative binding affinity and 170-fold greater relative
potency in transcription assays for ERb than ERa [32].
The doses selected for the present study, 0.5, 1 and 2
mg/kg body weight (designated LOW, MID and HIGH
respectively), bracket the 1 mg/kg dose employed in our
prior study [4]. They are also well within the range of
what other investigators have used to evaluate the func-
tional role of ERb in other estrogen sensitive neuroen-
docrine pathways in vivo [33-36] and thus below a dose
that might generate activity through ERa. We hypothe-
s i z e dt h a tD P Nw o u l dh a v ead o s ed e p e n d e n te f f e c to n
HPG de-feminization with the most significant effects
produced by the highest dose.
Methods
Experiment 1
Animal husbandry, neonatal exposure and surgery
Timed pregnant Long Evans rats (n = 10; Charles River,
NC, USA) were individually housed in polysulfone caging
within a humidity- and temperature-controlled room
with a 14-h light, 10-h dark cycle (lights on from 7:00 to
21:00) at 23°C and 50% average relative humidity at the
Biological Resource Facility at North Carolina State Uni-
versity (NCSU). Because standard lab chows are soy-
based and thus contain significant amounts of phytoes-
trogens [37-39], all of the animals were fed a phytoestro-
gen-free diet ad libitum for the duration of the
experiment (Test Diet 5K96, Purina). The dams littered
over three days and each day all newly arrived litters
were cross-fostered to minimize litter effects and culled
to a maximum litter size of 12. All of the pups within a
cross-fostered litter were then assigned to the same treat-
ment group to prevent cross contamination. Each treat-
ment group contained two cross-fostered litters and all
animals were treated, regardless of sex. Males remained
in the litter but were not used for this study.
Beginning on the day of birth, neonates were subcuta-
neously (sc) injected with vehicle (0.05 ml, Sigma, St.
Louis, MO, USA), estradiol benzoate (EB, 10 μg, Sigma),
or one of three doses of the ERb selective agonist diaryl-
propionitrile (DPN; 0.5, 1 or 2 mg/kg bw, Tocris Bios-
ciences, Ellisville, MS, USA). These doses were
designated LOW, MID, and HIGH respectively. All
compounds were dissolved in ethanol, then sesame oil
at a ratio of 10% EtOH and 90% oil as we have done
previously [27]. The vehicle was also prepared with this
ratio. We have found this vehicle to cause less skin irri-
tation than the alternative vehicle, DMSO. The 1 mg/kg
dose of DPN is approximately equivalent to what has
previously been used by us and others in vivo
[33,36,40-44]. The other two doses were selected to
bracket this dose. The range was narrow but the highest
dose was not anticipated to be high enough to activate
ERa [33-36]. DPN is an ERb selective agonist with a 70-
fold greater relative binding affinity and 170-fold greater
relative potency in transcription assays for ERb than
ERa [32]. The animals (n = 6 to 12 females per group)
received injections daily from the day of birth (postnatal
day (PND) 0) through PND 3 (four injections total).
All pups were weaned into same sex litter-mate pairs
on PND 21, ear punched and maintained on the same
light cycle as the dams. Upon weaning, the animals were
checked every morning for day of vaginal opening
(DOV), a hallmark of puberty in the rat. Because DOV
can be accelerated by increased body weight, all animals
were weighed on a single day after most animals had
undergone vaginal opening (all animals PND 29 or 30
on the day of weighing) to ensure body weights were
equivalent. Monitoring of the estrous cycle by vaginal
lavage [45] commenced approximately two weeks after
vaginal opening. Samples were collected on three conse-
cutive mornings every other week beginning on the pre-
dicted day of estrus. We opted to sample every other
week to reduce handling stress and minimize the poten-
tial for inducing a pseudopregnancy. All animals
observed to have stopped cycling (defined by the failure
to sequentially progress through proestrus, estrus and
diestrus) were reexamined (for three to five consecutive
days) two weeks later to confirm that the failure to cycle
was persistent and not due to a pseudopregnancy. Sam-
pling proceeded until PND 115.
Animals were ovariectomized (OVX) under isoflurane
anesthesia (completed over four days beginning on PND
150) and recovered for three weeks. The OVX females
were then injected sc with 10 μg EB dissolved in sesame
oil at 0900 h, followed 48 hours later by a sc injection
of 500 μg progesterone dissolved in the same vehicle to
stimulate a GnRH surge. Animals were then sacrificed
by transcardial perfusion (4% paraformaldehyde) six to
eight hours after the progesterone injection at the onset
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because this is the point at which GnRH activity peaks
using this experimental paradigm [46,47]. Blood was col-
lected by cardiac puncture prior to the onset of perfu-
sion. Brains were removed, post-fixed in 20% sucrose
paraformaldehyde, cryoprotected overnight in potassium
phosphate buffer containing 20% sucrose, rapidly frozen
in powdered dry ice, and stored at -80°C. Brains were
then sliced into 35 μm coronal sections, and divided
into two series of free-floating alternating sections. Tis-
sue was stored in antifreeze solution (20% glycerol, 30%
ethylene glycol in KPBS) at -20°C until immunohisto-
chemical processing.
Animal care, maintenance, surgery and sacrifice were
conducted in accordance with the applicable portions of
the Animal Welfare Act and the U.S. Department of
Health and Human Services “G u i d ef o rt h eC a r ea n d
use of Laboratory Animals.” All experimental procedures
involving animals were approved by the NCSU Institu-
tional Animal Care and Use Committee.
Immunohistochemistry
A subset of animals was used for the immunostaining (n
= 5 per group). From each of these animals, one set of
coronal sections comprising the organum vasculosum of
the lamina terminalis (OVLT) through the caudal border
of the anterior ventral periventricular nucleus (AVPV)
were immunolabeled for GnRH and Fos or Kiss using
immunohistochemistry (IHC) methods described in
detail elsewhere [4,20,48]. Briefly, the first set of tissue
was incubated in a cocktail of primary antibodies direc-
ted against GnRH (raised in rabbit, 1:8,000, and gener-
ously gifted by Dr. Robert Benoit of McGill University
Health Center, Montreal, QC, Canada) and Fos (raised
in goat, 1:250, Santa Cruz Biotechnology, Santa Cruz,
CA, USA; SC-52-6) followed by the secondary antibo-
dies Alexa-Fluor donkey anti-rabbit 488 and Alexa-Fluor
donkey anti-goat 555 at 1:400. The second set of tissue
was incubated in a primary antibody directed against
kisspeptin-10 [49] (raised in rabbit, 1:4,000, and gener-
ously gifted by Alain Caraty of Institut National de la
Recherche Agronomique/Centre National de la
Recherche Scientifique, Université de Tours, France)
and the Alexa-Fluor donkey anti-rabbit 488 secondary
antibody at 1:400. After secondary antibody incubation,
sections were rinsed, mounted onto slides (Superfrost
Plus, Fisher, Pittsburgh, PA, USA), and cover-slipped
with glycerol mountant (50% glycerol in 4 M sodium
bicarbonate).
Quantification of GnRH and Fos immunoreactivity
GnRH activation was assessed by quantifying the per-
cent of GnRH neurons co-localized with the early gene
product Fos (cFos), a method which is a reliable indi-
cator of GnRH activation [50] following OVX and hor-
mone priming. GnRH/Fos double-immunofluorescent
label was visualized and quantified as described in our
prior publications [4,5]. GnRH immunoreactive (-ir)
neurons were distributed laterally and dorsally to the
third ventricle throughout the OVLT and anterior
AVPV, as has been described previously [51]. Three
sequential sections per animal comprising the OVLT
through the midlevel region of the AVPV (correspond-
ing to 0.24 through -0.12 mm from Bregma) were
selected for analysis using a brain atlas for reference
[52]. Only tissue sets showing consistent GnRH and
Fos immunostaining throughout all sections were used
for the analysis. They were photographed with a Retiga
1800 monochrome camera (QImaging, Austin, TX
USA) attached to a Leica 5000DM microscope (Leica
Microsystems, Wetzlar, Germany) fitted with 20× and
40× objective lenses and filter cubes for Cy3 and FITC.
The images of each label (GnRH and Fos) were then
merged using the MCID Elite Image Analysis (Interfo-
cus Imaging Ltd., Cambridge, England, UK) software
package. Single labeled GnRH cells, and cells immuno-
labeled for both GnRH and Fos were then hand-
counted by an individual blind to the treatment groups
and verified by a second independent observer. As
expected [51,53], the average number of GnRH cells
counted per animal did not statistically differ between
groups.
Quantification of Kiss immunoreactivity in the AVPV and
ARC
In mice, Kiss immunoreactivity (-ir) has previously been
shown to be localized to extended lengths of fibers
throughout the AVPV and within cell bodies located in
the medial and caudal AVPV [21]. These cell bodies are
readily visible in mice but not in rats (point of discus-
sion, 1
st World Conference on Kisspeptin Signaling in
the Brain) unless an intracerebroventricular infusion of
colchicine is administered [54]. To overcome this tech-
nical hurdle, we have previously found that, in the rat,
quantitative assessment of AVPV Kiss-ir neuronal fibers
is a suitable and reliable alternative to counting Kiss-ir
cell bodies [4,20,30] and developed a method for doing
so by co-opting techniques used previously to quantify
neuronal fiber density in other brain regions [55,56].
This approach does not account for all Kiss immunola-
beling present in the entire region of interest but instead
gives a representative assessment of the density of label-
ing within the region. Thus, for the present study, in the
AVPV we quantified Kiss-ir fiber density.
In the ARC, Kiss perikarya are sparse but readily
labeled in the rat, along with a dense plexus of Kiss-ir
fibers [21,30,57]. Cell numbers do not appear to be
sexually dimorphic, but the density of Kiss-ir fibers is
[19,30]. Thus, for the present study, in the ARC we
quantified both Kiss-ir fiber density and cell bodies
using confocal microscopy. The total number of Kiss-ir
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lated for each animal.
To assess the density of AVPV Kiss-ir fibers projecting
rostrally from the AVPV to the OVLT GnRH neurons,
two to three rostral AVPV sections per animal were
selected using a brain atlas [52,58] (corresponding to 0.0
through 0.48 mm from Bregma). In the ARC, six
sequential sections comprising the rostral, middle and
caudal regions of the ARC (corresponding to -1.92
through -3.36 mm from Bregma) were selected from
each animal. Kiss-ir was visualized on a Leica TCS SPE
confocal microscope fitted with a 63× oil corrective
objective lens. For each scan, a set of serial image planes
(z-step distance = 1 μm) was collected through the
entire thickness of the section. Individual images were
acquired sequentially for light emitted from each fluoro-
phore and parsed into separate stacks of images for ana-
lysis using the Image J software package (National
Institutes of Health (NIH), Bethesda, MD, USA) as pre-
viously described [48]. To control for variations in tissue
thickness that would result in unequal numbers of
image planes, substacks of consecutive image planes
that excluded the rostral and caudal edges of the tissue
sections were created for each set of scans. Substacks
consisted of 23 sequential image planes for the AVPV
and 24 sequential images planes for the ARC. As we
have described previously [20,48], individual images con-
tained within each substack were depixelated and binar-
ized to minimize the inclusion of background
fluorescence. Fibers were then skeletonized to a thick-
ness of one pixel to compensate for differences in indivi-
dual fiber thickness and brightness. The number of
resulting bright pixels in each image plane was then
quantified using the Image J Voxel Counter plug-in
(NIH) and summed over the substack. The ARC sub-
stacks were then reviewed one at a time and Kiss-ir cell
bodies were counted by hand. The resulting number of
Kiss-ir voxels and Kiss-ir cell bodies is, therefore, a
quantitative representation of Kiss-ir density within the
volume sampled but is not meant to be an absolute
quantification of the number of Kiss-ir fibers (or cell
bodies) contained within the region of interest.
Serum LH analysis
Upon collection, blood samples were immediately spun
down in a refrigerated centrifuge for 10 minutes at
13,000 rpm. The plasma fraction (n = 5 per group) was
then removed and sent to the Biomarkers Core Lab at
the Yerkes National Primate Research Center at Emory
University (Atlanta, GA, USA) for analysis by radioim-
munoassay (RIA). The limit of detection was 1 ng/ml
and the intra-assay coefficient of variance was less than
10%. Animals with LH levels below the limit of detec-
tion were assigned a level of 1 ng/ml for the statistical
analysis.
Experiment 2
Neonatal exposure and tissue collection
To validate the Kiss data obtained from IHC, and to
determine approximately how early in development sig-
nificant effects are discernable, a second set of animals
was exposed and used to quantify Kiss1 mRNA levels.
Timed pregnant LE rats were obtained (n = 10) to gen-
erate pups for Experiment 2, cross-fostered, culled and
maintained under the same conditions as described in
Experiment 1. For this experiment, only the mid-level
dose of DPN was used, a group receiving 1 mg/kg PPT
and a group receiving both DPN and PPT (1 mg/kg
each) were included to determine if the co-administra-
tion of these compounds could replicate the masculiniz-
ing effect of EB. Thus, females were exposed to vehicle,
EB, MID DPN, PPT (1 mg/kg) or DPN+PPT (1 mg/kg
of each) by sc injection from PNDs 0 to 3. The animals
were then sacrificed by rapid decapitation on PND 24
(prior to pubertal onset) or 33 (just after pubertal onset)
and the brains rapidly removed and flash frozen on dry
ice then stored at -80°C. For each brain, serial sections
(20 μm thick) comprising the anterior border of the
OVLT through the caudal aspect of the ARC (as defined
in Experiment 1) were cut and slide mounted using a
cryostat. We have previously shown that sex differences
in Kiss1 mRNA are appreciable at this age in the AVPV
but not the ARC [30].
In situ hybridization for Kiss1 mRNA
Kiss1 mRNA levels were assessed using an in situ hybri-
dization (ISH) protocol described by us previously
[22,30]. Briefly, the cDNA transcriptional template gen-
erated to probe Kiss1 mRNA was a 318-bp cDNA insert
(Genbank Accession number NM_181692.1) prepared
by using reverse transcription-polymerase chain reaction
(RT-PCR) with a forward primer of 5’-TCTCCTCTG
TGTGGCCTCTT-3’ and a reverse primer of 5’-AGGC-
CAAAGGAGTTCCAGTT-3’. Following ISH, slides
were exposed to Kodak Biomax MR X-ray film (Eastman
Kodak, Rochester, NY, USA) for 11 days (AVPV) or 24
days (ARC) then developed using an automatic proces-
sor (Konica Corporation, Tokyo, Japan). 14C-labeled
autoradiographic standards (Amersham Pharmacia Bio-
tech, Piscataway, NJ, USA)) were included in the cas-
settes for quantification. X-ray film images viewed using
a monochrome QICAM 1394 12-bit camera (QImaging,
Surry, BC, Canada) mounted above a light-box (supplied
by InterFocus Imaging Ltd., Cambridge, England, UK).
Relative levels of Kiss1 mRNA in the AVPV and ARC
were assessed by optical density from the film autora-
diograms using the digital densitometry application of
t h eM C I DC o r eI m a g es o f t w a r ep r o g r a m( I n t e r F o c u s
Imaging Ltd., Cambridge, England, UK) following proce-
dures similar to what we and others have described pre-
viously [22,59-61]. For each region of interest (AVPV or
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interest was created and used for all sections to standar-
dize the area examined. Brain regions and background
levels were measured unilaterally from anatomically
matched sections. For each animal, three measurements
per region of interest were obtained (one each from the
rostral, medial and caudal regions) along with an unla-
beled background area at each point. The three values
obtained for each animal were then averaged to obtain a
representative measurement for that animal. Average
background levels were then subtracted to obtain a final
value. Optical densities were converted to nCi/g tissue
equivalents using autoradiographic 14C microscales
(Amersham Life Sciences, Arlington Heights, IL, USA).
Statistical analysis
For Experiment 1, DOV, body weight, plasma LH levels,
the percent of GnRH and FOS co-labeled cells, the
number of ARC Kiss-ir cells, and the density of voxels
containing Kiss immunolabeling within the OIL, EB,
LOW DPN, MID DPN and HIGH DPN groups were
compared by one-way analysis of variance (ANOVA)
with exposure group as the factor and followed up with
Fisher’s Least Significant Difference (LSD) post-hoc tests
for individual comparisons when appropriate (SYSTAT,
Systat Software, Inc., Chicago, IL, USA). For Experiment
2, Kiss1 mRNA levels were first compared by two-way
ANOVA with age and exposure group as factors, and
then followed up with the appropriate one-way ANOVA
and Fisher’sL S Dpost-hoc test. In all cases, comparisons




Age and weight at vaginal opening
There was a significant effect of exposure on DOV (F
(4,45) = 82.63, P ≤ 0.001). Compared to the vehicle trea-
ted controls (n = 12), DOV occurred approximately a
week earlier in the females neonatally exposed to EB
(Figure 1A, n = 6, P ≤ 0.001). DOV was also signifi-
cantly advanced by neonatal exposure to DPN in a dose
dependent fashion, with the DOV occurring earliest in
the group that received the highest dose (HIGH DPN, n
= 10, P ≤ 0.001). MID DPN advanced DOV by about
four days (n = 12, P ≤ 0.001) and LOW DPN advanced
DOV by approximately three days (n = 10, P ≤ 0.001).
There was no significant effect of treatment on body
weight (Figure 1B) around the time of DOV (F(4,45) =
1.259, P = 0.30), a result which indicates that weight
was not a confounding factor.
Estrous cycle data
Regular estrous cycles (Figure 1C) commenced in all
exposure groups except the group neonatally exposed to
EB. As expected [4,62], EB treated females (eight of
nine) failed to enter a normal estrous cycle and instead
displayed persistent estrus or diestrus. The one EB
female who initially began cycling entered a state of
anestrus within two weeks. Neonatal exposure to DPN
also resulted in the premature onset of irregular or
Figure 1 Effects on reproductive development. (A) Day of
vaginal opening (DOV), a hallmark of pubertal onset in the female rat,
was significantly advanced by EB and all doses of DPN compared
to the vehicle treated controls. (B) There was no overall effect of
treatment on bodyweight near the time of vaginal opening. (C) By 10
weeks of age, nearly all of the females neonatally administered EB or
the 2 mg/kg dose of DPN (HIGH DPN) were acyclic while all of the
vehicle control animals (Oil) were cycling normally. By 16 weeks of age,
75% of the MID DPN treated females and 85% of the LOW DPN
treated females were acyclic compared to only one of the control
females. (Means ± S.E.M., *P ≤ 0.001).
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Loss of a regular estrous cycle occurred earliest in the
HIGH DPN group (n = 10, Figure 1C), with only 20% of
these females progressing through all stages at 10 weeks
of age. In contrast, all of the vehicle treated control
females (n = 12) were displaying regular estrus cycles at
this age but only 68% (8 of 12) of the MID DPN females
and half of the LOW DPN females (5 of 10) were still
cycling normally. By 16 weeks of age, none of the EB or
HIGH DPN treated females were cycling compared to
all but one of the control females (92%), 25% of the
MID DPN females and 20% of the LOW DPN females.
Co-localization of GnRH and Fos in the OVLT
GnRH activation in response to the sequential admin-
istration of EB and progesterone was assessed by quan-
tifying the percent of GnRH and Fos co-labeling. There
was a significant effect of exposure group (F(4,17) =
10.029, P ≤ 0.001). Hormone administration success-
fully induced Fos-ir in 70% of GnRH neurons in the
vehicle treated control females (n = 5, Figure 2). In
contrast, less than 1% of GnRH neurons in EB treated
females were co-labeled with Fos (n = 4, P <0 . 0 0 1 )
demonstrating the potent defeminizing effect of EB on
this endpoint. Compared to the control females, GnRH
activation was lower in all of the DPN treated groups
(Figure 2B), the magnitude of which was most pro-
nounced at the highest dose (n = 5, P ≤ 0.001). None
of the DPN doses successfully replicated the magnitude
of the EB effect. The marginal effect of the 1 mg/kg
dose (n = 4, P = 0.07) is consistent with, and nearly
identical in magnitude to, what we have reported in a
past study [4].
Serum LH levels
Circulating LH levels (Figure 2C) were significantly
influenced by exposure group (F(4,20) = 2.91, P ≤ 0.04).
All of the animals (n = 5 per group) neonatally exposed
to EB, and three of the five animals in the HIGH DPN
group had LH levels below the limit of detection (1 ng/
ml). LH levels were significantly lower in the EB and
HIGH DPN groups compared to the vehicle treated
control group (P ≤ 0.05). A trend for lower LH levels in
the MID DPN group was also observed (P ≤ 0.06). The
overall pattern of serum LH levels was consistent with
the pattern of GnRH and Fos co-labeling (Figure 2).
Density of Kiss-ir in the AVPV
Kiss-ir in the AVPV was primarily visualized as extended
lengths of fibers and significantly affected by group (F
(4,16 = 3.762, P ≤ 0.02). As expected [4,20] the density of
Kiss-ir fibers was significantly lower in the females neo-
natally exposed to EB (P ≤ 0.005, n = 4) compared to the
vehicle treated controls (Figure 3, n = 4). The effect of
neonatal DPN exposure was dose dependent but the
curve was u-shaped rather than linear with the most sig-
nificant reduction in AVPV Kiss-ir occurring in the MID
Figure 2 GnRH activation and LH release following hormone
priming. (A) Immunolabeling of GnRH (green) and FOS (red) in the
region surrounding the OVLT following hormone priming
(Experiment 1). Representative double labeled cells are indicated by
the blue arrows and single labeled GnRH neurons are indicated by
the white arrows. Double labeled cells were first visualized at low
magnification and then verified at higher magnification (inset). (B)
The percentage of double labeled neurons was significantly
reduced by neonatal DPN administration but the magnitude of the
effect was substantially greater in the EB treated group. (C) LH
levels were below the limit of detection (indicated by the red line, 1
ng/ml) in all females neonatally exposed to EB, and three of the five
animals in the HIGH DPN group. LH levels were significantly lower
in the EB and HIGH DPN groups compared to the vehicle treated
control group (OIL, P ≤ 0.05). A trend for lower LH levels in the MID
DPN group was also observed (P ≤ 0.06). The overall pattern of
serum LH levels was largely reflective of GnRH and FOS co-labeling.
(3v = 3
rd ventricle, Means ± S.E.M., *P ≤ 0.05, **P ≤ 0.001, † < 0.07).
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Page 7 of 14DPN (1 mg/kg) group (Figure 3; P ≤ 0.03, n = 4). Kiss-ir
fiber density was slightly lower than vehicle controls in
the LOW DPN (P = 0.27, n = 4) and the HIGH DPN (P
= 0.62) groups but the effect was not significant in either
case.
Kiss-ir fibers and cells in the ARC
There was an overall effect of group (F(4,17 = 7.086; P ≤
0.002) on the density of Kiss-ir fibers in the ARC but
this was entirely driven by the significantly lower levels
in the EB treated females (Figure 4, n = 4) compared to
the vehicle treated control females (n = 5, P ≤ 0.001).
DPN did not impact the density of Kiss-ir fibers in the
ARC regardless of dose. Immunolabeled perikarya did
not significantly differ between groups (F(4,17 = 0.130,
P = 0.969).
Experiment 2
Kiss1 mRNA expression in the AVPV
Labeling was readily discernable and evenly distributed
throughout the entire AVPV of the PND 24 and 33
(Figure 5A) animals. Two-way ANOVA revealed a
significant effect of age (F(1,49) = 64.009; P ≤ 0.001) and
exposure group (F(4,49) = 24.284; P ≤ 0.001) as well as a
significant interaction (F(4,49) = 10.074; P ≤ 0.001) on
Kiss1 mRNA levels in the AVPV (Figure 5B). As antici-
pated, levels increased with age in all groups except the
EB group. Within the PND 24 animals, there was a sig-
nificant effect of exposure (F(4,24) = 7.161; P ≤ 0.001).
Compared to vehicle controls, females exposed to EB,
PPT or DPN+PPT had significantly lower Kiss1 mRNA
Figure 3 Kisspeptin immunolabeling in the anterior
hypothalamus. Fluorescence photomicrographs showing Kiss
immunoreactive (-ir) labeling in the AVPV of the hormone primed
females (Experiment 1). (A) Kiss-ir was localized to extended lengths
of fibers within and surrounding the AVPV. (B) Kiss-ir fibers (blue
arrows) were readily visible and quantifiable at high magnification
with the confocal microscope. The density of Kiss immunostaining
was significantly lower in the EB and MID DPN (1 mg/kg) treated
groups compared to the control animals. (3v = 3
rd ventricle, ox =
optic chiasm, (A) Scale bar = 50 μm, (B) Scale bar = 25 μm, Means
± S.E.M., *P ≤ 0.05, **P ≤ 0.005).
Figure 4 Kisspeptin immunolabeling in the mediobasal
hypothalamus. Fluorescence photomicrographs showing Kiss
immunoreactive (-ir) labeling in the ARC of the hormone primed
females (Experiment 1). Kiss immunolabeling was considerably
denser (A) than in the AVPV (see Figure 3) and localized to both
fibers, (B blue arrows) as well as a small number of cell bodies that
were often difficult to discern from the heavy fiber labeling (B,
white arrows). (C) The density of Kiss-ir labeling was significantly
lower in the females neonatally treated with EB but not DPN at any
dose examined. (D) The number of Kiss-ir cell bodies did not
statistically differ between groups. (3v = 3
rd ventricle, (A) Scale bar =
50 μm, (B) Scale bar = 25 μm, Means ± S.E.M., **P ≤ 0.001).
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Page 8 of 14Figure 5 Hypothalamic kisspeptin mRNA expression in peripubertal females. (A) Representative autoradiographs depicting Kiss1 mRNA
signal in the AVPV of periputertal females (Experiment 2). (B) Expression was significantly higher in the control (OIL) group compared to the
PPT, DPN+PPT and EB groups at both PND24 and 33. (C) Within the ARC, expression was only significantly lower in the EB group compared to
the OIL controls at both ages examined. Expression was not significantly altered in any of the other groups. (Scale bar = 500 μm, **P ≤ 0.005).
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Page 9 of 14levels (P ≤ 0.001 in all cases). Levels in the DPN animals
were also lower, but not significantly so (P = 0.08).
These differences were even more pronounced on PND
33 (post-pubertal onset). Again there was a main effect
of exposure group (F(4,25) = 20.083; P ≤ 0.001) and the
EB, PPT and DPN+PPT females had significantly lower
Kiss1 mRNA levels compared to the control females (P
≤ 0.001 in all cases). DPN exposed female Kiss1 mRNA
levels were not significantly different from controls.
Kiss1 mRNA expression in the ARC
Labeling in the ARC was even more robust than in the
AVPV and evenly distributed between the rostral and
caudal borders. Two-way ANOVA revealed a significant
effect of age (F(1,48) = 12.932; P ≤ 0.001) and exposure
group (F(4,48) = 5.516; P ≤ 0.001) but no significant
interaction on Kiss1 mRNA levels in the ARC (Figure
5 C ) .O nP N D2 4t h e r ew a sas i g n i f i c a n te f f e c to fe x p o -
sure (F(4,24) = 3.731; P ≤ 0.02) with only the EB group
having significantly lower expression levels than the
controls (P ≤ 0.005). Similarly, on PND 33 there was
also a significant effect of group (F(4,24) = 3.463; P ≤
0.023) and again only the EB exposed animals had lower
expression compared to controls (P ≤ 0.005).
Discussion
Neonatal agonism of ERb by DPN, at the three doses
examined, produced only moderate disruption of the
HPG axis. Physiological impacts included advanced vagi-
nal opening and premature anestrus. A diminished capa-
city to elicit Fos labeling in GnRH neurons in response
to hormone priming was observed, and although it cor-
responded with lower LH levels, this effect only reached
statistical significance at the highest dose. Impacts on
the kisspeptin system were minimal. Reduced Kiss-ir
fiber density within the AVPV was only observed at the
1 mg/kg dose and no effects on ARC Kiss-ir were
observed. Moreover, peripubertal Kiss1 mRNA levels
were not significantly affected by DPN in the AVPV or
ARC. In contrast, AVPV expression was significantly
abrogated by EB or the ERa agonist PPT. These obser-
vations are consistent with what we have reported pre-
viously using the 1 mg/kg dose of DPN [4] and support
the hypothesis that ERa plays a more substantial role
than ERb in the estrogen-dependent defeminization of
hypothalamic steroid positive feedback signaling path-
ways during the neonatal critical period.
There was a dose dependent effect of neonatal DPN
administration on DOV, a hallmark of puberty in the
rat. Although all three doses significantly advanced pub-
ertal onset, none resulted in a DOV as early as the ani-
mals exposed to EB. Body weight can be a confounding
factor in the timing of pubertal onset, with heavier ani-
mals progressing through puberty earlier than lighter
animals. This does not appear to have been the case
here because there was no significant effect of exposure
on body weight. Body weights were equivalent across
the groups, and the heaviest animals were in the vehicle
treated control group. The1m g / k gd o s eo fD P N( M I D
DPN) advanced puberty by about four days, a shift that
is considerably larger than what we have observed pre-
v i o u s l y[ 4 ] .F o rt h ep r e s e n ts t u d yw eu s e dn e a r l yt w i c e
as many animals so this difference may at least be par-
tially attributable to the resulting increased statistical
power or to other factors we cannot readily account for,
such as time of year or quality of maternal care. The
specific mechanisms by which estrogen exposure
advances DOV remain unclear. Because exogenous
administration of kisspeptin has been shown to advance
puberty [63,64], one possibility is that early DOV results
from the premature stimulation of GnRH neurons by
kisspeptin. The present results are not consistent with
this idea, however, because Kiss1 expression was not
elevated in the PND 24 or PND 33 females that ulti-
mately displayed early DOV. In contrast, AVPV levels
were significantly decreased in EB exposed females, an
effect more indicative of masculinization.
Neonatal agonism of ERb also significantly curtailed
the capacity to maintain a regular estrous cycle. The
effect was dose dependent with animals in the group
administered the highest dose generally entering a state
of anestrus earlier than animals given the lower two
doses. By PND 70, more than half of the females in the
MID and LOW DPN groups were still cycling, at a
point long after nearly all females neonatally exposed to
EB or PPT become anestrus [4]. The observation that
the administration of either PPT or DPN can limit the
duration over which the estrous cycle progresses nor-
mally is consistent with results obtained in a prior
study, using different ER selective agonists [65]. In that
study, agonism of ERb was found to have a more potent
effect on estrous cyclicity than agonism of ERa,ar e s u l t
opposite to what we have observed. This could result
from the binding and transcriptional properties of the
selective agonists, or the timing of exposure. Collec-
tively, however, it is evident from these findings that
premature anestrus can result from neonatal exposure
to estrogen agonists.
Even though selective agonism of ERb was not as
effective as EB (or PPT) in defeminizing steroid positive
feedback on GnRH, it was not completely inconsequen-
tial, as the capacity to induce GnRH and Fos co-labeling
was reduced by nearly half at the LOW and MID doses
and by nearly two-thirds at the HIGH dose. Corre-
spondingly lower LH secretion was also observed, but
only at the highest dose. This dose dependent effect of
DPN reveals that the capacity to generate GnRH and
Fos co-labeling must be abrogated by at least half before
appreciable disruption of gonadotropin secretion occurs.
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numerous examples where neural cell loss or dysfunc-
tion must be substantial before physiological effects are
observed. A notable example is Parkinson’s disease, in
which upwards of 60 to 70% of dopaminergic nigrostria-
tal neurons must be lost before motor symptoms mani-
fest [66].
Although it is generally accepted that hormonal sig-
nals are largely conveyed to GnRH neurons by other
hormone sensitive neurons within the hypothalamus,
GnRH neurons constitutively express ERb throughout
development [67-69]. Therefore, it is at least theoreti-
cally possible that the partial impairment of steroid posi-
tive feedback on GnRH neurons resulted from the direct
activation of ERb on GnRH neurons themselves. Neona-
tal DPN exposure did not affect the number of GnRH
neurons in the anterior hypothalamus, a finding which
is consistent with other studies examining the impact of
developmental exposure to estrogens or estrogen-like
compounds on GnRH neurons [51,53,70], so this cannot
be the mechanism by which GnRH neuronal activation
was curtailed. An alternative possibility is that DPN
acted on other ERb expressing neurons within the
hypothalamus. It is appealing to predict that DPN acted
on AVPV Kiss-ir neurons directly, but this hypothesis
may prove difficult to test. In the adult female rat,
nearly all Kiss-ir neurons are found to be co-localized
with either ERa or (to a lesser degree) ERb [71] but it
appears that neither Kiss1 mRNA nor Kiss-ir are detect-
able until approximately two weeks after birth
[21,22,57]. It is likely that this neuronal population is
present but quiescent during this time, but this remains
to be clearly established. Thus, it is plausible that early
life exposure alters the sex specific organization and
function of this neuronal population. A biomarker for
these neurons in early neonatal life would be needed to
test this hypothesis. Consistent with this idea, however,
we have recently shown that there are marked sex dif-
ferences in ERa and ERb mRNA expression in the neo-
natal rat AVPV [22] with females having higher levels of
ERa, but males having higher ERb levels than females,
on the day of birth. This sex difference could at least
partially account for why females appear to be more
sensitive to the masculinizing influence of ERa agonists
at this age. It is also possible that ERb-expressing neu-
rons with afferents to AVPV Kiss neurons, rather than
Kiss neurons themselves, are mediating the decrease in
Kiss-ir and GnRH activity. If this is the case, it remains
to be determined what those neurons might be. In addi-
tion, selective activation of ERb might have impacted
the expression of ERa in the AVPV, and our subsequent
observations, therefore, reflect changes in ERa activity
[72]. It has long been hypothesized that each ER subtype
modulates the expression and activity of the other in a
region specific manner [73-75] and this balance may
have been disrupted by DPN administration. Regardless
of how or where DPN is stimulating ERb activity, our
data show that the net result is only a marginal decrease
in AVPV Kiss-ir and GnRH neuronal activation in the
adult female.
The impact of DPN on the organization of Kiss-ir in
the female AVPV was dose dependent but, unlike the
other endpoints we examined, the dose response curve
was u-shaped rather than linear. Maximal reduction was
observed at the middle (1 mg/kg) dose. In contrast, the
suppression of GnRH activation by DPN was approxi-
mately equivalent across all three DPN doses and thus
consistent with Kiss1 mRNA levels (Figure 5), but not
concomitant with the u-shaped dose effect on AVPV
Kiss-ir levels. It is not readily clear why this one end-
point, and not the others, produced a u-shaped response
curve or what the functional significance of it might be.
It may simply be a spurious observation, a possibility
consistent with the failure to find an appreciable effect
of DPN on AVPV Kiss1 expression in peripubertal
females. Notably this nonmonotonic type of dose
response curve is not atypical for estrogen or estrogen
agonists. For example, a biphasic effect of estradiol on
terminal end bud formation in the mammary gland and
prostate hyperplasia have been described previously
[76,77]. A definitive mechanism to explain this phenom-
enon is lacking, but several hypotheses have been put
forth, including the differential regulation of hormone
receptors with dose, and the overlap of two distinct
mechanisms of action [78]. For the present study, both
hypotheses are plausible. In the MID DPN females, LH
levels are lower but not significantly so, indicating that
the lower numbers of Kiss-ir fibers may have functional
significance. Normal levels in the HIGH DPN females
may reflect a method by which the system is attempting
to compensate for decreased GnRH sensitivity to steroid
hormone stimulation. Further studies incorporating
serial sampling of LH are needed to explore these
possibilities.
Kiss fiber density and mRNA expression was reduced
in the ARC of the EB but not the DPN exposed animals,
an effect which was not completely unexpected given
that ERb does not appear to be present in the neonate
[22] or adult female ARC [79,80]. Many of these fibers
likely originate from the AVPV population [81]. Collec-
tively, the data presented here suggest that ERb agonism
does not alter the density of this plexus. More perplex-
ing, however, Kiss1 mRNA expression was not affected
by neonatal PPT exposure nor the combination of DPN
and PPT. The significant effect of EB is consistent with
what we have seen previously, but remains somewhat
surprising given that neither the number of Kiss neu-
rons nor the quantity of Kiss1 expression in the ARC
Patisaul et al. Biology of Sex Differences 2012, 3:2
http://www.bsd-journal.com/content/3/1/2
Page 11 of 14have been found to be sexually dimorphic in rats [26]. It
remains to be determined why neonatal EB administra-
tion has such a profound effect on a population of neu-
rons that do not appear to be sexually dimorphic or
what the functional significance of this might be. It also
remains to be established why the co-administration of
DPN and PPT did not recapitulate the effect of EB. It is
possible that EB is acting at the level of the membrane
or via a “non-classical” pathway to induce the effect
[82,83].
As discussed previously, the doses of DPN chosen for
this study were selected to bracket the dose of 1 mg/kg
that we and others have used before [4,33]. Because
DPN has only a 70-fold greater relative binding affinity
for ERb than ERa [32], at high doses it may also begin
to bind and activate ERa. Although the highest dose
used for the present studies (2 mg/kg) has been success-
fully employed by others with no evidence of ERa agon-
sim [36], it is possible that agonism of ERa occurred to
some degree. Partial agonism of ERa could explain why
the HIGH DPN females had earlier puberty and lost
their estrous cycle more quickly than those in the other
two DPN groups, and why GnRH activation was some-
what lower at this dose compared to the other two.
Even if agonism of ERa occurs at this dose, from the
totality of the data it is evident that agonism of ERb
alone was insufficient to affect any of the endpoints
observed to the same degree as EB.
Conclusion
In summary, neonatal estrogen defeminizes the hypotha-
lamus such that the coordination of steroid positive
feedback on GnRH neurons and, consequently, the
maintenance of a regular ovulatory cycle are curtailed.
The AVPV population of Kiss neurons is also sexually
differentiated by neonatal estrogen and believed to be
pivotal for initiating the pre-ovulatory surge of GnRH
[12,25]. Here we have shown that neonatal administra-
tion of the ERb agonist DPN does not affect the onto-
geny of Kiss1 expression across peripuberty or induce
functional Kiss/GnRH signaling disruptions, resulting in
abrogated LH release, at a dose below 2 mg/kg. These
results indicate that selective agonism of ERb is not suf-
ficient to completely achieve the male-typical HPG phe-
notype seen with either EB or PPT.
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